CD274 and neoplasm: TAMs affect the therapeutic effects of PD-1/PD-L1 inhibitors by regulating the PD-L1 expression in tumour cells, secreting a variety of cytokines to create a tumour-supporting TME and neutralise anti-PD-1/PD-L1 through their Fc-ɣ receptors [50–55].